VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Stock Now Rated “Reduce” by Wall Street Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned an average recommendation of “Reduce” from the five analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $0.95.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Monday, August 31st.

VistaGen Therapeutics Stock Performance

VTGN stock traded down $0.00 during trading on Friday, hitting $0.16. The stock had a trading volume of 517,772 shares, compared to its average volume of 817,755. The company’s 50 day moving average price is $0.23 and its two-hundred day moving average price is $0.43. VistaGen Therapeutics has a 1-year low of $0.16 and a 1-year high of $5.14. The stock has a market cap of $7.27 million, a price-to-earnings ratio of -0.10 and a beta of 0.49.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. The company had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, sell-side analysts forecast that VistaGen Therapeutics will post -1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VTGN. ADAR1 Capital Management LLC acquired a new position in shares of VistaGen Therapeutics in the 2nd quarter worth $79,000. BlackRock Inc. purchased a new stake in shares of VistaGen Therapeutics during the second quarter valued at $78,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of VistaGen Therapeutics by 81.2% during the first quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after purchasing an additional 130,509 shares during the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.

Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.